Abstract: A compound represented by the following general formula (I): [wherein R1 and R2 represent a C1-6 alkyl group; R3, R4 and R5 represent hydrogen atom, a C1-6 alkyl group, or an aryl group; Y1 and Y2 represent —O—, —S—, —Se—, —CH?CH—, —C(R6)(R7)—, or —N(R8)— (wherein R6, R7 and R8 represent hydrogen atom or a C1-6 alkyl group); A represents a C1-3 alkylene group; n and n? represent 0, 1 or 2; Z1 and Z2 represent a nonmetallic atom group required to form a benzo-condensed ring or a naphtho-condensed ring; L1 to L7 represent a methine group; and M? represents a counter ion in a number required for neutralizing electrical charge], which is useful as a fluorescent probe of which optical characteristics change depending on pH change.
Abstract: The invention provides a method of inhibiting the effects of platelet activating factor (PAF). For instance, a disease or condition mediated by PAF (particularly inflammation) can be treated or platelet aggregation can be inhibited. The invention also provides a method of inhibiting the production and/or release of interleukin 8 (IL-8) by cells. The effects of PAF and the production and/or release of IL-8 are inhibited according to the invention by a compound of the formula: wherein R1 and R2 are defined in the application, or a physiologically-acceptable salt thereof. The invention also provides pharmaceutical compositions comprising these compounds.
Type:
Grant
Filed:
March 25, 2003
Date of Patent:
June 4, 2013
Assignee:
DMI Acquisition Corp.
Inventors:
David Bar-Or, C. Gerald Curtis, Nagaraja K. R. Rao, Greg Thomas
Abstract: A medicament for promoting proliferation of hepatocytes and liver regeneration, which comprises a polyprenyl compound such as 3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid as an active ingredient.
Type:
Grant
Filed:
May 4, 2012
Date of Patent:
June 4, 2013
Assignees:
Josai University Educational Corporation, Kowa Company, Ltd.
Inventors:
Masahiko Ogihara, Mitsutoshi Kimura, Naoto Ishibashi, Jun Kojima
Abstract: A pharmaceutical acceptable composition is provided. The composition comprises an effective amount of a non-steroidal anti-inflammatory drug (NSAID), a local anesthetic, and an antiviral drug.
Abstract: The invention provides supramolecular metal complexes as DNA cleaving agents. In the complexes, charge is transferred from one light absorbing metal (e.g. Ru or Os) to an electron accepting metal (e.g. Rh) via a bridging ?-acceptor ligand. A bioactive metal-to-metal charge transfer state capable of cleaving DNA is thus generated. The complexes function when irradiated with low energy visible light with or without molecular oxygen.
Type:
Grant
Filed:
November 2, 2009
Date of Patent:
May 21, 2013
Assignee:
Virginia Tech Intellectual Properties, Inc.
Abstract: The invention provides a method of inhibiting the effects of platelet activating factor (PAF). For instance, a disease or condition mediated by PAF (particularly inflammation) can be treated or platelet aggregation can be inhibited. The invention also provides a method of inhibiting the production and/or release of interleukin 8 (IL-8) by cells. The effects of PAF and the production and/or release of IL-8 are inhibited according to the invention by a compound of the formula: wherein R1 and R2 are defined in the application, or a physiologically-acceptable salt thereof. The invention also provides pharmaceutical compositions comprising these compounds.
Type:
Grant
Filed:
September 29, 2011
Date of Patent:
May 14, 2013
Assignee:
DMI Acquisition Corp.
Inventors:
David Bar-Or, C. Gerald Curtis, Nagaraja K. R. Rao, Greg Thomas
Abstract: The invention relates to compounds that are useful as immunosuppressive agents and for treating and preventing inflammatory conditions, allergic disorders, and immune disorders.
Abstract: The present invention relates to a method for stabilizing vegetable, marine and single cell oils/oil concentrates as well as pigments like astaxanthin and canthaxanthin with regard to oxidation. It also relates to a feed for salmonids, and a method for optimising the effect of the pigment in feed for salmonids. Furthermore, the invention relates to a health care product and a composition for prophylaxis or therapeutical treatment. Essential features by the invention are treatment by or presence of amines/amides.
Type:
Grant
Filed:
December 20, 2000
Date of Patent:
February 26, 2013
Assignee:
Pronova Biopharma Norge AS
Inventors:
Harald Breivik, Lola Irene Sanna, Berit Annie Aanesen
Abstract: The present invention relates to provide an aflatoxin production inhibitor that inhibits aflatoxin production specifically and efficiently, is highly safe, and is practical, and an efficient production method thereof; and a method for controlling aflatoxin contamination that uses the aflatoxin production inhibitor, specifically relating to an aflatoxin production inhibitor that includes at least one of a dioctatin represented by the following formula (I) and a derivative thereof, as an active ingredient: where, in the formula (I), R represents one of hydrogen and a methyl group.
Type:
Grant
Filed:
December 19, 2011
Date of Patent:
February 26, 2013
Assignees:
Microbial Chemistry Research Foundation, The University of Tokyo
Abstract: The present invention provides a compound having an excellent inhibitory action on melanin production and being useful as a whitening agent, and a skin external preparation containing the compound. The whitening agent of the present invention comprises, as an active ingredient, a compound represented by formula (1) or a pharmacologically acceptable salt thereof: wherein, R1, R3, R4, and R6 are each independently C1-3 alkyl; and R2 and R5 are each independently a hydrogen atom or C1-3 alkyl.
Abstract: The present invention relates to pyrazinone derivatives of formula (I): wherein R1, R2, R3, R4, R5, R6 and R7 are as herein defined; processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
Type:
Grant
Filed:
March 6, 2012
Date of Patent:
October 30, 2012
Assignee:
AstraZeneca AB
Inventors:
Stephen Brough, Richard Evans, Timothy Jon Luker, Piotr Raubo
Abstract: The present invention provides a PPAR ? agonist comprising, as an active ingredient, a tricyclic compound represented by the formula (I) (wherein R1 represents lower alkyl optionally having substituent(s) or the like, R2 and R3 are the same or different and each represents lower alkyl optionally having substituent(s) or the like, R4 and R5 are the same or different and each represents a hydrogen atom or the like, Q1-Q2-Q3 represents CH?CH—CH?CH or the like, Y represents a single bond or the like, Z1-Z2 represents C?CR13 (wherein R13 represents a hydrogen atom or the like), or the like, and A represents —COOH or the like), or a pharmaceutically acceptable salt thereof and the like.
Abstract: Disclosed are fluorescent compounds useful as intracellular pH probes. In particular, the invention teaches a two-photon absorbing, water soluble, fluorescent compound, a fluorene derivative, which is effective as a near-neutral pH indicator and particularly as an intracellular probe. A method for chemical synthesis of the claimed compounds is provided.
Type:
Grant
Filed:
July 7, 2008
Date of Patent:
July 31, 2012
Assignee:
University of Central Florida Research Foundation, Inc.
Abstract: A pharmaceutical composition for topical administration for prevention and/or treatment of diseases associated with decrease in bone mass comprising an EP4 agonist as an active ingredient. An EP4 agonist, in which includes a compound possessing prostaglandin skeleton as a representative, possesses promoting action on bone formation, so it is useful for prevention and/or treatment of diseases associated with decrease in bone mass (bone diseases such as primary osteoporosis, secondary osteoporosis, bone metastasis of cancer, hypercalcemia, Paget's disease, bone loss and bone necrosis, postoperative osteogenesis, alternative therapy for bone grafting).
Abstract: A pharmaceutical preparation comprising EPA in an appropriately assimilable form where of all the fatty acids present in the preparation at least 90%, and preferably at least 95%, is in the form of EPA and where less than 5%, and preferably less than 3%, is in the form of DHA is provided.
Abstract: The present invention relates to a composition which includes a moiety of formula wherein R1, R2, R3 and R4 each represent n-pentyl, and to a method of sterilizing a su fluid using same.
Type:
Grant
Filed:
May 12, 2008
Date of Patent:
May 29, 2012
Assignee:
Photopharmica Limited
Inventors:
Stanley Beames Brown, Cassandra Claire O'Grady, John Griffiths, Kirste Joanne Mellish, David Ian Vernon
Abstract: Provided herein are aminoquinolones and pharmaceutically acceptable derivatives thereof. In certain embodiments, provided herein are compounds, compositions and methods for treating, preventing or ameliorating GSK-3 mediated diseases.
Type:
Grant
Filed:
March 13, 2007
Date of Patent:
November 22, 2011
Assignee:
Kyorin Pharmaceutical Co., Ltd.
Inventors:
Oana Cociorva, Bei Li, Anna Katrin Szardenings, Yasumichi Fukuda, Masahiro Nomura, Shigeki Seto, Kazuhiro Yumoto, Kyoko Okada, Ayako Nakamura
Abstract: Compounds that bind S100 and inhibit the S100-p53 protein-protein interaction and activate the tumor suppressor activity of p53, and thus which have an antineoplastic effect are disclosed, as well as methods for identifying these compounds, compositions comprising the same, and methods of using the same to treat cancer.
Type:
Grant
Filed:
March 27, 2003
Date of Patent:
November 8, 2011
Assignee:
University of Maryland, Baltimore
Inventors:
David J. Weber, Joseph Markowitz, France Carrier, Alexander D. MacKerell
Abstract: We describe methods and compositions for treating a patient suffering from a hyperproliferative disorder or photoageing. Our methods involve blocking the activity of a retinol binding protein receptor (RBPr) in cells of the patient, and/or administering to the patient an antagonist of a retinol binding protein receptor (RBPr) and/or lowering the endogenous level of retinoic acid (RA) in cells of said patient.
Type:
Grant
Filed:
February 27, 2002
Date of Patent:
November 1, 2011
Assignee:
Vampex Limited
Inventors:
Simon Ward, Claes Bavik, Michael Cork, Rachid Tazi-Aahnini